NEWS HIGHLIGHTSMedia Articles Related to Attenuvax (Measles Vaccine)
Autism, Measles Vaccine: No Link
Source: MedicineNet German Measles Specialty [2008.09.04]
Title: Autism, Measles Vaccine: No Link
Category: Health News
Created: 9/4/2008
Last Editorial Review: 9/4/2008
10 Technologies That Made News In 2009 And Warrant Watching In 2010
Source: Immune System / Vaccines News From Medical News Today [2009.11.17]
A first-of-its kind inhalable measles vaccine for developing countries, where the disease remains a scourge. A "nanogenerator" that could recharge iPods and other electronic devices with a shake. And for Fido and Fluffy, a long-awaited once-a-month pill for both ticks and fleas. It's list season, the time to prepare inventories of what stood out in 2009 and holds promise for the year ahead.
Published Studies Related to Attenuvax (Measles Vaccine)
Knowledge synthesis of benefits and adverse effects of measles vaccination: the Lasbela balance sheet. [2009.10.14]
ABSTRACT : BACKGROUND : In preparation for a cluster-randomized controlled trial of a community intervention to increase the demand for measles vaccination in Lasbela district of Pakistan, a balance sheet summarized published evidence on benefits and possible adverse effects of measles vaccination...
Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. [2009.05.05]
Two doses of measles-mumps-rubella vaccine (MMR) are widely recommended and consideration is being given to a similar schedule for varicella vaccine. A combined measles-mumps-rubella-varicella vaccine (MMRV) could be considered for this second dose in children previously vaccinated separately with MMR and varicella vaccines...
Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. [2009.04.14]
BACKGROUND: When this trial was initiated, the combined measles, mumps and rubella (MMR) vaccine was licensed for subcutaneous administration in all European countries and for intramuscular administration in some countries, whereas varicella vaccine was licensed only for subcutaneous administration. This study evaluated the intramuscular administration of an MMR vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) compared with the subcutaneous route... CONCLUSION: The immunogenicities of M-M-RvaxPro and VARIVAX administered by the intramuscular route were comparable with those following subcutaneous administration, and the tolerability of the two vaccines was comparable regardless of administration route. Integration of both administration routes in the current European indications for the two vaccines will now allow physicians in Europe to choose their preferred administration route in routine clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov NCT00432523.
Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. [2008.08]
BACKGROUND: Measles, mumps, and rubella (MMR) and varicella (V) vaccines are often coadministered at 1 clinic visit. This study (104389/NCT00127023) was undertaken to assess the immunogenicity and safety of a new refrigerator-stable tetravalent MMRV vaccine after 1 dose and after 2 doses administered during the second year of life... CONCLUSIONS: Both after 1 dose and after 2 doses, the MMRV vaccine was at least as immunogenic as concomitant MMR and varicella vaccination suggesting that it could be suitable for use according to current vaccination schedules.
Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. [2008.07.24]
OBJECTIVE: To examine the protective efficacy of measles vaccination in infants in a low income country before 9 months of age... CONCLUSIONS: In low income countries, maternal antibody levels against measles may be low and severe outbreaks of measles can occur in infants before the recommended age of vaccination at 9 months. Outbreaks of measles may be curtailed by measles vaccination using the Edmonston-Zagreb vaccine as early as 4.5 months of age. TRIAL REGISTRATION CLINICAL TRIALS: NCT00168558 [ClinicalTrials.gov].
Clinical Trials Related to Attenuvax (Measles Vaccine)
A Measles, Mumps, and Rubella Investigational Vaccine Trial [Completed]
The purpose of this study is to test the safety of a measles, mumps, and rubella study
vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA
(recombinant human albumin).
Prophylactic Antibiotics in Measles [Completed]
Objective It is the objective to test whether the use of prophylactic antibiotics in measles
infection will reduce the incidence of post-measles pneumonia and/or admissions to hospital
with 50%. The possible impact on other complications of severe measles will also be
measured.
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases [No longer recruiting]
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases [Completed]
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases [Completed]
|
